186 drugs not sold in hospitals (with list)

Medicine Network November 2nd, with the implementation of a batch of national collection, the minimum price reduction requirements for unseeded drugs are constantly refreshed, there will be a large number of pharmaceutical companies face not significant price reductions, kick out of the market status quo.
186 drugs, suspended procurement October 31, Jiangsu Province drug sunshine procurement and comprehensive supervision platform announced the "third batch of state-organized drug centralized procurement of unseeded product prices notice."
the same time, the document also attached to the "suspended procurement of part of Jiangsu Province drug sunshine procurement of online products" publicity form, a total of 186 drugs were suspended procurement.
Cypress Blue combing found that the suspension of the procurement of varieties involving a number of well-known pharmaceutical companies, such as Jiangsu Zhengdafenghai's hydrochloric acid Moxisa star sodium chloride injection, Chongqing Core Pharmaceuticals (Group) Co., Ltd. and North China Pharmaceuticals' Amocrin particles, Yi Changdong Sunshine Changjiang Pharmaceutical Co., Ltd.'s Kramycin dispersion tablets, Hunan Colum Pharmaceutical Co., Ltd.'s Amoxilin particles, China Resources Shuanghe Pharmaceutical Co., Ltd.'s Pivastatin calcium tablets (film coats), Stone Pharmaceutical Group's Ohi Pharmaceutical Co., Ltd. methylcobalamin tablets ... The suspension of procurement action, to go back to September 30, Jiangsu Province Medical Security Bureau issued a document "on the third batch of national organizations to do a good job in the implementation of the results of centralized procurement of drugs", the document on the price adjustment and use of unseeded drugs to make provisions: the provincial platform in the third batch of drugs listed in the national collection of unseeded drugs, should be required to adjust the price before they can continue to hang up the network.
(1) Original research drugs, compared preparations, through the consistent evaluation (hereinafter referred to as consistent evaluation) generic drugs: has been in other provinces gradient price reduction, the production enterprises should be in other provinces after the gradient price reduction of the lowest price as the upper limit, the initiative to apply for adjustment of the list price;
(2) Failure to evaluate generic drugs through consistency: Production enterprises shall actively apply for adjustment of the list price with the lowest price in the current implementation price of each provincial (district, city) of the product and the lower of the selected price of the same variety in the third batch of national collection "National Drug Centralized Procurement (Jiangsu)".
the same variety of drugs through the consistent evaluation of the production enterprises reached more than 3, did not pass the consistent evaluation of generic drugs suspended the network.
medical institutions can ensure that the agreed procurement volume of the selected drugs can be completed, according to the actual clinical needs and usage habits, the appropriate amount of procurement of the use of provincial platform hanging network prices appropriate for the unseeded drugs.
That is to say, for the national collection of unseeded varieties, must be in accordance with the relevant requirements of Jiangsu Province price adjustment, in order to continue to hang up the network, if refused to adjust, it is equivalent to the loss of Jiangsu Province, a huge pharmaceutical market. More than
documents call for price reduction, otherwise the suspension of procurement this year, Jiangsu Province has issued a number of documents in a row to make large-scale adjustments to the prices of online products: its December 2, 2019 release of the Jiangsu Provincial Medical Security Bureau on the implementation of the 2019 Jiangsu Province drug centralized procurement catalog drug price dynamics The notice of adjustment work clearly states that, in order to improve the drug procurement system in Jiangsu Province, to give full play to the role of dynamic adjustment of drug procurement prices in promoting the formation of uniform prices for the same products and different regions of pharmaceutical production enterprises, and to reduce the prices of some virtually high varieties, it was decided to carry out dynamic adjustment to the provincial finalist prices of some drugs in the centralized drug procurement catalogue of Jiangsu Province.
the final results, 5,336 drugs were suspended during the dynamic adjustment, meaning that a large number of drugs will no longer be purchased by medical institutions in Jiangsu Province from August 1.
In accordance with the above-mentioned dynamic adjustment notice, for the "2015 Jiangsu Province Drug Centralized Procurement Implementation Program" procurement catalogue of some drugs (specific scope includes: large quantities of drugs, dosing of small drugs, low-cost drugs, record drugs, alternative drugs and through quality consistency evaluation of drugs, innovative drugs), to take the national provincial (district, city) is now implementing the lowest price linkage, encourage enterprises to reduce prices independently, with enterprises with different specifications should be reasonable price.
the current provincial finalist price after evaluation.
If the enterprise does not fill in the complete information within the prescribed time limit, it is better to fill in the actual report of the national provincial (district, city) is now implementing the lowest price in the price, providing false materials and other acts, once confirmed will be interviewed, the serious circumstances of the suspension of the product online qualification.
According to the notice, the same varieties through the consistent evaluation of the production enterprises to reach more than 3 unapprecoored drugs, after passing the consistent evaluation can be in accordance with the "on the promotion of drug sunshine procurement implementation opinion (trial)" provisions of the re-declaration;
And the national minimum price is the price before the evaluation of the adoption of consistent evaluation of drugs, may temporarily restore the relevant drug network qualification, but it must be in accordance with the "Implementation Opinion" requirements to actively complete the national minimum price adjustment, not timely completion of price adjustment, in accordance with the "Implementation Opinion" provisions.
Overall, now over-consistent evaluation is no longer the deadly throat of pharmaceutical companies - price is, as a major pharmaceutical province, Jiangsu's price reduction initiatives in the country have a weather-heading role, pharmaceutical companies if they can not achieve the standards and requirements for price reduction, will be directly suspended from the internet.
with the implementation of a batch of national collection, the minimum price reduction requirements for un selected drugs are also constantly refreshed, there will be a large number of pharmaceutical companies face not significant price reductions, kicked out of the market status quo.